semaglutide alcohol use disorder clinical trial RCT: reduces craving and consumption - Knopf - 2025 - Alcoholism & Drug Abuse Weekly side effects of drinking alcohol

GIPR-deficient mice diet-induced obesity , GIPR antagonism AT-7687 GLP-1RA

Some conditions that cause night sweating include: Sleep apnea: A severe sleep disorder where a person repeatedly stops breathing in their sleep

180 mcg

Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial

Regeneron is also collaborating with AstraZeneca on small-molecule, GPR75-targeting obesity drugs based on their own genetic research

Glucagon-like peptide-1 (GLP-1) agonists are the latest evolution of drugs that are reshaping the way we treat diabetes, obesity, and other forms of addiction.